Search Results Search Sort by RelevanceMost Recent Policy Forum Feb 2017 Seeking Legitimacy for DSM-5: The Bereavement Exception as an Example of Failed Process James E. Sabin, MD and Norman Daniels, PhD The DSM-5 Task Force’s handling of the ethical controversy over the bereavement exclusion demonstrates the need for more inclusive deliberative processes. AMA J Ethics. 2017;19(2):192-198. doi: 10.1001/journalofethics.2017.19.2.pfor2-1702. Medicine and Society Oct 2023 What Might Aducanumab Teach Us About Clinicians’ Judgment About Whether to Recommend Emerging Alzheimer’s Interventions? Adam W. Burroughs, MD and Lewis P. Krain, MD Ethics questions about care of patients with AD could influence clinicians’ judgment about whether and when to recommend aducanumab. AMA J Ethics. 2023;25(10):E777-782. doi: 10.1001/amajethics.2023.777.
Policy Forum Feb 2017 Seeking Legitimacy for DSM-5: The Bereavement Exception as an Example of Failed Process James E. Sabin, MD and Norman Daniels, PhD The DSM-5 Task Force’s handling of the ethical controversy over the bereavement exclusion demonstrates the need for more inclusive deliberative processes. AMA J Ethics. 2017;19(2):192-198. doi: 10.1001/journalofethics.2017.19.2.pfor2-1702.
Medicine and Society Oct 2023 What Might Aducanumab Teach Us About Clinicians’ Judgment About Whether to Recommend Emerging Alzheimer’s Interventions? Adam W. Burroughs, MD and Lewis P. Krain, MD Ethics questions about care of patients with AD could influence clinicians’ judgment about whether and when to recommend aducanumab. AMA J Ethics. 2023;25(10):E777-782. doi: 10.1001/amajethics.2023.777.